Market Place
Sourcing Support
Copper-67 SAR-bisPSMA updates
16 Oct 2024 //
PR NEWSWIRE
Positive FDA Guidance On 64Cu-SAR-bisPSMA Phase III Trial
14 Oct 2024 //
PR NEWSWIRE
SECuRE Trial Shows Promising Data In First Multi-Dose Cohort
12 Sep 2024 //
PR NEWSWIRE
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
22 Aug 2024 //
PR NEWSWIRE
NorthStar Medical Radioisotopes Enters Clinical Supply Pact
10 Apr 2024 //
CONTRACTPHARMA
First Participant Treated Using NorthStar Med Radioisotopes’ (Cu-67)
28 Aug 2023 //
BUSINESSWIRE
First participant treated at the highest dose level in Clarity`s mCRPC trial
25 Aug 2023 //
PR NEWSWIRE
Clarity establishes a US Center of Excellence for Targeted Copper Theranostics
28 Jun 2023 //
PR NEWSWIRE
Clarity commences COMBAT theranostic prostate cancer trial in the US
20 Jun 2023 //
PR NEWSWIRE
Clarity completes first stage of prostate cancer trial
25 May 2023 //
CLINICAL TRIALS ARENA
IND approval from FDA for theranostic SAR-Bombesin trial in prostate cancer
21 Nov 2022 //
PRNEWSWIRE
Clarity begins subject dosing in prostate cancer therapy trial
10 Oct 2022 //
CLINICALTRIALSARENA
First patient treated in Clarity`s therapeutic prostate cancer trial
07 Oct 2022 //
PRNEWSWIRE
First participant imaged in PII SAR-Bombesin prostate cancer trial in the US
06 Oct 2022 //
PRNEWSWIRE
First patient treated in the US-based prostate cancer imaging trial
21 Apr 2022 //
PRNEWSWIRE
Clarity`s US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens recruitment
28 Mar 2022 //
PRNEWSWIRE
New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer
24 Mar 2022 //
PRNEWSWIRE
First patient treated in cohort 2 SARTATE neuroblastoma therapy trial
25 Feb 2022 //
PRNEWSWIRE
US FDA Study May Proceed letter for Clarity`s Cu-64 SAR-bisPSMA trial
07 Feb 2022 //
PRNEWSWIRE
Clarity and Evergreen Enter Clinical Manufacturing Agreement
05 Oct 2021 //
CONTRACTPHARMA
Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement
30 Sep 2021 //
PRNEWSWIRE
First patient treated in Clarity`s Cu-64/Cu-67 SAR-bisPSMA cancer trial
25 Aug 2021 //
PRNEWSWIRE
Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
28 Jul 2021 //
PRNEWSWIRE
Shaemus Gleason Appointed Executive Vice President US Operations at Clarity
11 May 2021 //
PRNASIA
Clarity Pharmaceuticals closes $25m capital raising
15 Dec 2020 //
PRNEWSWIRE
Clarity Pharmaceuticals closes $25m capital raising
15 Dec 2020 //
PRNASIA
Clarity Pharmaceuticals opens SARTATE neuroblastoma clinical trial
23 Jul 2020 //
PRNSIA
Clarity Pharmaceuticals opens SARTATE neuroblastoma clinical trial
22 Jul 2020 //
PRNEWSWIRE
Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets
21 Jul 2020 //
PRNASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.